SEC Tracker
Get the app

Damora Therapeutics DMRA

OrbiMed Genesis Master Fund (Shareholder) plans to sell 75,473 DMRA shares, about $56,605

Form
144
Filed
Importance
Routine
  1. Approximate sale date: Aug 15, 2023
  2. Broker: Bank of America
  3. Shares acquired by: Private placement

All of OrbiMed Genesis Master Fund's insider filings, holdings and planned sales

Written from the Form 144 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Damora Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. China Pharma Holdings CPHI public float $4M, Jun 30, 2025
  2. Soligenix SNGX public float $5M, Jun 30, 2025
  3. Theriva Biologics TOVX public float $4M, Jun 30, 2025
  4. Polomar Health Services PMHS public float $4M, Jun 30, 2025
  5. Enveric Biosciences ENVB public float $4M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.